Key facts
- NanoSynex’s last known valuation is $850K (Jun 2022).
- It has raised $650K; the latest was Later Stage VC ($500K) in Jan 2025.
- Notable investors include Arieli Innovate, Horizon 2020.
- Status: Acquired/Merged (Operating Subsidiary).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for NanoSynex
- ·The full record, as it builds
Funding rounds
No funding rounds for NanoSynex are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NanoSynex
Developer of a rapid antimicrobial susceptibility test (AST) designed to enable faster prescription of targeted antibiotics for bacterial infections. The company's tests use a phenotypic approach with a microfluidic disposable test card that optimises bacterial growth, enabling healthcare providers to reduce diagnostic time, assist in antibiotic selection, and support efforts to control antimicrobial resistance in clinical settings.
- Sector
- Healthcare
- HQ
- Ness Ziona, Israel
- Founded
- 2017
- Employees
- 12
- Website
- nanosynex.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
NanoSynex doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NanoSynex shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NanoSynex in its N-PORT filings yet. We sweep new filings monthly.